In conclusion, this study suggests that ERCC1 expression levels negatively contribute to the clinical outcomes including PFS and OS in patients treated with cisplatin-based CCRT for locally advanced SCCHN. This evidence concerns the gene ERCC1 and head and neck squamous cell carcinoma.